HSPG2

Across TCGA pan-cancer cohorts, HSPG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HSPG2 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher HSPG2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HSPG2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where HSPG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.830	1.000	.003	27	view →
LUAD	DFS	Tertile	II,III,IV	0.406	0.865	.005	22	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	DFS	Quartile	III,IV	0.744	0.396	.009	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HSPG2–LSCC (DFS)

Open the LSCC breakdown →